Just like Millenium with Velcade, SGEN will not survive as an independent entity. Segal will not accept less than 75 though. That is where an independent SGEN trades in 2 years with all of the new indications...The problem for Takeda is that Roche would suck this thing up first. And it s not about Adcetris either. Its' all about the technology... There are so many drugs on the horizon that Roche cannot afford to let the opportunity pass. All just my opinion.